And TRANSCEND-T2D-1, part of a separate three-trial diabetes-specific program, confirmed -2.0% HbA1c reduction and 16.8% weight loss in 537 type 2 diabetes patients (topline March 2026, published in The Lancet, June 2026)
Another important white space is represented by the emergence of comorbidity-driven positioning of oral obesity drugs, which allows marketing such medicines as treatment not only for weight loss but also for obesity associated with type 2 diabetes, cardiovascular risks, metabolic syndrome, and MASH
bag - $43 at Chewy Best budget wet: Blue Buffalo True Solutions Weight Control Chicken Recipe, 3 oz
Do you really have to get blood work before you can even start
Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders